For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of BioAtla Inc (NASDAQ: BCAB) closed at $0.49 in the last session, down -1.86% from day before closing price of $0.50. In other words, the price has decreased by -$1.86 from its previous closing price. On the day, 0.52 million shares were traded.
Ratios:
We take a closer look at BCAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.52 and its Current Ratio is at 3.52. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 15, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.
Credit Suisse Downgraded its Outperform to Neutral on May 05, 2022, whereas the target price for the stock was revised from $35 to $5.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.58 while its Price-to-Book (P/B) ratio in mrq is 1.98.
Stock Price History:
Over the past 52 weeks, BCAB has reached a high of $3.53, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 37.40%, while the 200-Day Moving Average is calculated to be -58.64%.
Shares Statistics:
A total of 58.10M shares are outstanding, with a floating share count of 45.38M. Insiders hold about 22.31% of the company’s shares, while institutions hold 39.52% stake in the company.
